Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
neuraminidase inhibitor
|
| gptkbp:appointed_by |
intravenous injection
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:class |
neuraminidase inhibitors
|
| gptkbp:clinical_trial |
Phase III trials
hospitalized patients Phase II and III 100% (IV) acute uncomplicated influenza |
| gptkbp:composed_of |
gptkb:chemical_compound
|
| gptkbp:contraindication |
hypersensitivity to peramivir
|
| gptkbp:developed_by |
gptkb:Bio_Cryst_Pharmaceuticals
|
| gptkbp:dosage_form |
600 mg once daily
|
| gptkbp:duration |
5 days
|
| gptkbp:education |
important for understanding use
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
peramivir
|
| gptkbp:ingredients |
C16 H20 N2 O4
|
| gptkbp:interacts_with |
gptkb:oseltamivir
gptkb:zanamivir limited interactions |
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
J05 A H05
|
| gptkbp:is_effective_against |
demonstrated in trials
reduces duration of symptoms |
| gptkbp:is_used_for |
treatment of influenza
|
| gptkbp:lifespan |
20 hours
|
| gptkbp:manager |
IV
|
| gptkbp:market |
2014 in the US
|
| gptkbp:marketed_as |
gptkb:Rapivab
|
| gptkbp:pharmacokinetics |
inhibits viral replication
rapid distribution part of antiviral regimen |
| gptkbp:population |
immunocompromised patients
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
WHO recommendations
CDC recommendations |
| gptkbp:regulatory_compliance |
internationally recognized
|
| gptkbp:research |
ongoing studies for efficacy
|
| gptkbp:research_areas |
various universities
|
| gptkbp:research_focus |
influenza virus strains
|
| gptkbp:safety_features |
generally well tolerated
monitored in clinical trials |
| gptkbp:sales |
available in multiple countries
|
| gptkbp:side_effect |
headache
nausea allergic reactions diarrhea elevated liver enzymes |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
patients with severe renal impairment
|
| gptkbp:target_audience |
adults and children over 2 years
|
| gptkbp:treatment |
within 48 hours of symptom onset
|
| gptkbp:type_of |
198470-85-8
|
| gptkbp:type_of_care |
important for effectiveness
|
| gptkbp:weight |
304.34 g/mol
|
| gptkbp:bfsParent |
gptkb:influenza_B
gptkb:influenza_B_virus |
| gptkbp:bfsLayer |
6
|